<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Diaz-Ortiz ME</submitter><funding>NIA NIH HHS</funding><funding>NINDS NIH HHS</funding><pagination>eabk0637</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9870036</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>377(6608)</volume><pubmed_abstract>Many risk loci for Parkinson's disease (PD) have been identified by genome-wide association studies (GWASs), but target genes and mechanisms remain largely unknown. We linked the GWAS-derived chromosome 7 locus (sentinel single-nucleotide polymorphism rs199347) to &lt;i>GPNMB&lt;/i> through colocalization analyses of expression quantitative trait locus and PD risk signals, confirmed by allele-specific expression studies in the human brain. In cells, glycoprotein nonmetastatic melanoma protein B (GPNMB) coimmunoprecipitated and colocalized with α-synuclein (aSyn). In induced pluripotent stem cell-derived neurons, loss of &lt;i>GPNMB&lt;/i> resulted in loss of ability to internalize aSyn fibrils and develop aSyn pathology. In 731 PD and 59 control biosamples, GPNMB was elevated in PD plasma, associating</pubmed_abstract><journal>Science (New York, N.Y.)</journal><pubmed_title>GPNMB confers risk for Parkinson's disease through interaction with α-synuclein.</pubmed_title><pmcid>PMC9870036</pmcid><funding_grant_id>R01 NS082265</funding_grant_id><funding_grant_id>U19 AG062418</funding_grant_id><funding_grant_id>F31 NS113481</funding_grant_id><funding_grant_id>K23 NS114167</funding_grant_id><funding_grant_id>R01 NS115139</funding_grant_id><funding_grant_id>P50 NS053488</funding_grant_id><funding_grant_id>P30 AG072979</funding_grant_id><pubmed_authors>Skrinak RT</pubmed_authors><pubmed_authors>Brody EM</pubmed_authors><pubmed_authors>Jain N</pubmed_authors><pubmed_authors>Charan R</pubmed_authors><pubmed_authors>Luk KC</pubmed_authors><pubmed_authors>Unger TL</pubmed_authors><pubmed_authors>Van Deerlin VM</pubmed_authors><pubmed_authors>Han N</pubmed_authors><pubmed_authors>Diaz-Ortiz ME</pubmed_authors><pubmed_authors>Clark E</pubmed_authors><pubmed_authors>Weintraub D</pubmed_authors><pubmed_authors>Posavi M</pubmed_authors><pubmed_authors>Gallagher MD</pubmed_authors><pubmed_authors>Davila-Rivera R</pubmed_authors><pubmed_authors>Seo Y</pubmed_authors><pubmed_authors>Carceles Cordon M</pubmed_authors><pubmed_authors>Zack R</pubmed_authors><pubmed_authors>Chen-Plotkin AS</pubmed_authors><pubmed_authors>Amari N</pubmed_authors><pubmed_authors>Lee EB</pubmed_authors><pubmed_authors>Tropea TF</pubmed_authors></additional><is_claimable>false</is_claimable><name>GPNMB confers risk for Parkinson's disease through interaction with α-synuclein.</name><description>Many risk loci for Parkinson's disease (PD) have been identified by genome-wide association studies (GWASs), but target genes and mechanisms remain largely unknown. We linked the GWAS-derived chromosome 7 locus (sentinel single-nucleotide polymorphism rs199347) to &lt;i>GPNMB&lt;/i> through colocalization analyses of expression quantitative trait locus and PD risk signals, confirmed by allele-specific expression studies in the human brain. In cells, glycoprotein nonmetastatic melanoma protein B (GPNMB) coimmunoprecipitated and colocalized with α-synuclein (aSyn). In induced pluripotent stem cell-derived neurons, loss of &lt;i>GPNMB&lt;/i> resulted in loss of ability to internalize aSyn fibrils and develop aSyn pathology. In 731 PD and 59 control biosamples, GPNMB was elevated in PD plasma, associating</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2025-04-22T10:14:58.757Z</modification><creation>2025-04-05T23:30:13.628Z</creation></dates><accession>S-EPMC9870036</accession><cross_references><pubmed>35981040</pubmed><doi>10.1126/science.abk0637</doi></cross_references></HashMap>